Rem3dy Health raises £500,000 to develop 3D-printed personalized vitamin supplements

Home > Hardware

October 1, 2025 Hardware 515

The new funding aims to expand manufacturing capacity, increase production, and strengthen Rem3dy Health's presence in key markets such as the United States and Asia.

3D-printed nutrient products manufactured in Rem3dy's UK laboratory. Image from Rem3dy Health.

UK-based health tech company Rem3dy Health, headquartered in the Midlands, has secured a £500,000 SAFE investment from Future Planet Capital Regional through the West Midlands Combined Investment Fund. This investment is part of a larger £9 million funding plan. Other investors include the Japanese beverage and health group Suntory, the American nutrition and agriculture company ADM, and the French pharmaceutical company UPSA.

3D Printing Powers Personalized Nutrition

Consumers are increasingly seeking alternatives to traditional vitamins, which often come in the form of multiple pills, contain synthetic additives, and use plastic packaging. Rem3dy Health addresses this demand through its Nourished brand. Nourished utilizes patented 3D printing technology to create customized, seven-layer nutrient gummies. These "stacked" products use food-derived ingredients and are free from artificial additives.

To date, Rem3dy Health has raised £19 million, established three manufacturing plants, secured 29 approved patents, and developed new manufacturing technologies to expand its product range.

Rem3dy Health founder and CEO Melissa Snover, who has previously founded and scaled multiple businesses in the West Midlands, plans to involve local investors in this funding round.

Snover stated: "Securing this new investment from Future Planet Capital Regional and the West Midlands Combined Investment Fund is a significant milestone for Rem3dy Health. Having a strong West Midlands investor join us is particularly meaningful and will further solidify our roots in this dynamic region. This funding is crucial for expanding our production capacity and growing our global presence as we continue our mission to provide truly personalized and sustainable health solutions."

3D-printed nutritional composite product. Image from Rem3dy Health.

The Investor's Perspective

Future Planet Capital Regional highlighted Rem3dy's 3D-printed personalized nutrition products as a practical, natural, and sustainable method for enhancing vitamin intake. This technology holds promise for increasing efficiency and reducing environmental impact within the health and wellness industry.

Rupert Lyle, Investment Director at Future Planet Capital Regional and Fund Lead for the WMCO Fund, said: "We are tremendously excited about what the company has achieved. It not only offers a more effective and convenient way to take vitamins but also uses natural, food-derived materials without artificial additives, making its products safer and healthier for consumers. This aligns perfectly with our fund's commitment to supporting innovative and impactful businesses."

Rachel Brothwood, Executive Director for Pensions, added: "We are proud to see the West Midlands Combined Investment Fund supporting Rem3dy Health, a company rooted in our region that is pushing the boundaries of healthcare innovation. We are committed to backing businesses that not only create local jobs and economic growth but are also competitive on a global scale. This investment is a prime example of how regional capital can help ambitious companies scale up, make a tangible impact, and showcase the strength of the West Midlands on the world stage."

Developments in the 3D Printing Medical Field

The investment in Rem3dy Health reflects a broader shift in the application of 3D printing technology within the healthcare sector—from nutrition to pharmaceuticals. The technology enabling personalized nutrient combinations is also driving innovation in drug manufacturing.

In August, the private non-profit tech organization Battelle and 3D pharmaceutical company Aprecia received an agreement from the US Defense Advanced Research Projects Agency (DARPA). This supports the "Establishment of QUALIFICATION Processes for Agile Pharmaceutical Manufacturing" (EQUIP-A-Pharma) research project funded by the US Department of Health and Human Services (HHS) Administration for Strategic Preparedness and Response (ASPR) Office of Industrial Base Management and Supply Chain (IBMSC). The EQUIP-A-Pharma project will explore integrating Battelle's customized small-scale chemical synthesis platform with Aprecia's Z-Form Flex 3D printing technology to accelerate US drug production and deliver high-quality, sustainable medicines.

Furthermore, the Chinese pharmaceutical 3D printing company Triastek recently announced its 3D-printed drug product D23—a Budesonide Ileum-Targeted Tablets for the treatment of IgAN (Immunoglobulin A Nephropathy), a kidney disease characterized by the buildup of Immunoglobulin A (IgA) deposits in the kidneys. The D23 drug showed positive efficacy in a recent clinical study. D23 is a Budesonide sustained-release tablet produced using the Melt Extrusion Deposition (MED) process, which Triastek has adapted through its proprietary 3D Microstructure for Intestinal Targeting (3DμS-IT) platform. This platform facilitates the precise release and delivery of the drug to the ileum, thereby enhancing the tablet's therapeutic effect.